The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Addressing cardiotoxicity associated with BTKis in patients with CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses her approach to addressing cardiotoxicity risks for patients with chronic lymphocytic leukemia (CLL). Cardiotoxicity, particularly atrial fibrillation and hypertension, are known issues with BTK inhibitors (BTKis). Strategies to mitigate these risks include fixed-duration regimens and more selective treatments, with BTKI selection tailored to each patient’s cardiac risk profile. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
